Zydus Lifesciences Ltd
ZYDUSLIFE price chart
Daily close · 5-year history
Instrument details
Identifiers & classification
- Symbol
- ZYDUSLIFE
- MB Code
- MBEQU5613
- ISIN
- INE010B01027
- BSE code
- 532321
- Industry group
- Pharmaceuticals & Biotechnology
- Screener
- View peers →
Latest earnings
Most recent declared quarter
- Quarter
- Mar 2026
- Revenue
- 7587 Cr
- Net profit
- 1341.3 Cr
- EPS
- 12.65
- YoY revenue
- +16.22%
Company documents
12 PDFs across 4 categories
Audited annual reports & financial statements
Earnings call transcripts & Q&A
Investor decks & strategy updates
Exchange filings & corporate announcements
Corporate timeline
Earnings, news & corporate actions for ZYDUSLIFE
Buyback up to ₹1,150 per share
Tender Offer · ₹1100 Cr aggregate
Buyback up to ₹1,260 per share
Tender Offer · ₹1100 Cr aggregate
Zydus Lifesciences' arm Zydus Therapeutics got FDA priority review for saroglitazar in PBC; the PDUFA target action date is November 27, …
Zydus Lifesciences jumped over 6% to a life high after Q4FY26 results showed 16% revenue growth, 8.7% higher net profit and brokerages tu…
EPS 16.60 vs est. 8.61
Beat estimates by 92.84%
Zydus Lifesciences beat Q4FY26 estimates, with revenue up 16% to ₹7,587 crore and adjusted net profit up 15%. It also guided for high-tee…
Zydus Lifesciences board approved a Rs 1,100 crore buyback on 19 May 2026 for up to 95,65,217 shares at Rs 1,150 each, a move that can su…
Zydus Lifesciences will acquire US-based Assertio Holdings for about $166.4 million, gaining ROLVEDON and a specialty oncology sales plat…
Price returns
Historical performance
Technicals
Indicator consensus